Incidence and severity grading of treatment-related adverse event associated with programmed death-1/programmed death-ligand 1 inhibitors combined with various anticancer regimens
- VernacularTitle:程序性死亡受体-1/程序性死亡受体-配体1抑制剂联合不同方案抗癌治疗的相关不良事件发生率及其严重程度分级
- Author:
Ting FENG
1
;
Ying QU
;
Lian LIU
;
Lin WANG
Author Information
- Keywords: malignant neoplasms; programmed death-1; programmed death-ligand 1; treat-ment-related adverse event; targeted therapy; specific immunity; non-specific immunity
- From: Journal of Clinical Medicine in Practice 2025;29(2):19-23
- CountryChina
- Language:Chinese
- Abstract: Objective To analyze the incidence and severity grading of treatment-related adverse event(TRAE)associated with programmed death-l/programmed death-ligand 1(PD-1/PD-L1)in-hibitors combined with various anticancer regimens.Methods A total of 356 tumor patients treated with PD-1/PD-L1 inhibitors were retrospectively selected as the study objects.The occurrence of ad-verse reactions in patients treated with PD-1/PD-L1 inhibitors combined with different anticancer regi-mens was recorded and analyzed.Results Among the 356 patients treated with PD-1/PD-L1 inhibi-tors in combination with various anticancer regimens,332 times of TRAEs were observed.Fatigue and adverse gastrointestinal reactions were the most prevalent,accounting for 31.93％(106/332)and 20.78％(69/332)respectively.Skin-related adverse reactions(appearing within 3 to12 weeks)and gas-trointestinal adverse reactions(5 to 10 weeks)occurred first,while fever(10 to 30 weeks)and pneumonia(12 to 32 weeks)presented later,with the longest observation time span.The lowest overall incidence of TRAE was observed in the combination of PD-1/PD-L1 inhibitors with cytotoxic T-lymphocyte-as-sociated antigen 4(CTLA-4)inhibitors(85.71％,36/42),while the highest was in the combina-tion with platinum-based doublet chemotherapy(96.88％,155/160).The incidence of grade 3 to 5 TRAEwas lowest in the combination of PD-1/PD-L1 inhibitors with radiotherapy(10.53％,6/57)and highest in the combination with vascular endothelial growth factor/vascular endothelial growth factor receptor(VEGF/VEGFR)targeted therapy(44.64％,25/56).There was no signifi-cant difference in the incidence and severity of TRAE among different tumors(P＞0.05).Conclu-sion When different anti-cancer regiments combined with PD-1/PD-L1 inhibitors,the overall inci-dence of TRAE is higher,among which the incidence of TRAE combined with CTLA-4 is relatively lowest,and the symptoms of TRAE combined with radiotherapy are relatively mild.
